Search Results - targeted+therapy

3 Results Sort By:
IL7Rα-Specific Antibody for Treating Acute Lymphoblastic Leukemia (ALL)
Abstract: Acute lymphoblastic leukemia (ALL) is the most common cancer in children with approximately 3,250 new cases occurring per year in the United States. About 20% of cases are refractory to current treatment protocols and there is a desperate need for targeted therapies that do not result in adverse side effects such as cognitive impairment.  The...
Published: 4/8/2024   |   Inventor(s): Scott Durum, Julie Hixon, Wenqing Li, Scotch Walsh, Lila Kashi
Keywords(s): Acute lymphoblastic leukemia (ALL), ANTIBODY, Antibody-Dependent Cellular Cytotoxicity (ADCC), Autoimmunity, CANCER, DIABETES, Durum, Interleukin-7 receptor-α (IL-7Rα), Multiple sclerosis, personalized medicine, Targeted therapy, THERAPY, TRANSPLANTATION
Category(s): Collaboration Sought > Licensing, Application > Therapeutics, TherapeuticArea > Oncology, Collaboration Sought > Collaboration
Near-IR Light-Cleavable Antibody Conjugates and Conjugate Precursors
Abstract: This invention describes a general way to trigger the release of a bioactive small molecule from a targeting antibody. The key “trigger” is a fluorescent linker that is chemically disassembled upon irradiation with light in the near-IR range (~800 nm). This linker technology is a dramatic step forward for the field. The molecules can be tracked...
Published: 4/8/2024   |   Inventor(s): Martin Schnermann, Alexander Gorka, Hisataka Kobayashi, Roger Nani
Keywords(s): ADC, Antibody-drug Conjugate, Chemical linkers, Fluorescent linker, PDT, personalized medicine, Photodynamic therapy, Targeted drug release, Targeted therapy
Category(s): TherapeuticArea > Oncology, Collaboration Sought > Collaboration, Collaboration Sought > Licensing, Application > Therapeutics
A Novel Device to Produce Autologous Serum Eye Drops at the Point of Care (Case No. 2021-198)
SUMMARY: UCLA researchers in the Stein and Doheny Eye Institutes have designed a device that can produce autologous serum eye drops at the point-of-care, greatly reducing the cost and complexity of the production process. BACKGROUND: Ocular surface diseases afflict hundreds of millions of people per year worldwide. Autologous serum eye drops benefit...
Published: 9/29/2023   |   Inventor(s): Justin Karlin
Keywords(s): Human Serum Albumin, Medical Devices and Materials, Targeted Therapy, Therapeutics & Vaccines
Category(s): Life Science Research Tools > Lab Equipment, Therapeutics > Ophthalmology